Global Antiemetic Drug Market 2017-2021

  • ID: 4312724
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • bbott
  • Eisai
  • Glenmark
  • IPCA Laboratories
  • Merck
  • RedHill
  • MORE
Emesis is defined as forceful expulsion of stomach content either due to humoral stimulation due to chemoreceptor trigger zone (CRTZ) or neural stimulation of emetic centers. The various drugs that are used to treat this condition of emesis are known as antiemetics. The various classes of drug available for management of emesis are serotonin antagonist, dopamine antagonist, NK1 receptor antagonist, antihistaminic, steroids, and anticholinergic. The various applications of antiemetic drugs include chemotherapy, surgery, gastroenteritis, morning sickness, motion sickness, stress-induced emesis, and drugs-induced emesis. This market is primarily volume driven as majority of drugs are available in generic form.

The report forecasts that the global antiemetic drug market to grow at a CAGR of 6.13% during the period 2017-2021.

Covered in this report:

The report covers the present scenario and the growth prospects of the global antiemetic drug market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
This report, Global Antiemetic Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion operating in this market.

Key vendors:
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
Other prominent vendors:
  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai
  • Eli Lilly
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • IPCA Laboratories
  • Lupin
  • Merck
  • Novartis
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
Market drivers:
  • Increased prevalence of cancer
  • For a full, detailed list, view this report
Market challenges:
  • Lack of animal models
  • For a full, detailed list, view this report
Market trends:
  • Inorganic growth strategies
  • For a full, detailed list, view this report
Key questions answered in this report:
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • bbott
  • Eisai
  • Glenmark
  • IPCA Laboratories
  • Merck
  • RedHill
  • MORE
Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: An overview of emesis

Part 06: Market landscape
  • Market overview
  • Five forces analysis
Part 07: Pipeline landscape

Part 08: Market segmentation by application
  • Chemotherapy
  • Surgery
  • Gastroenteritis
  • Others
Part 09: Market segmentation by drug class
  • 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
  • Dopamine antagonist
  • Neurokinin-1 (NK 1) receptor antagonist
  • Cannabinoid receptor antagonist
  • Others
Part 10: Geographical segmentation
  • Antiemetic drug market in Americas
  • Antiemetic drug market in EMEA
  • Antiemetic drug market in APAC
Part 11: Decision framework

Part 12: Drivers and challenges
  • Market drivers
  • Market challenges
Part 13: Market trends
  • Inorganic growth strategies
  • Guidelines for CINV drug development
  • Antiemetic oral soluble films
Part 14: Vendor landscape
  • Competitive scenario
Part 15: Key vendor analysis
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • Other prominent vendors
Part 16: Appendix

List of abbreviations

List of Exhibits
Exhibit 01: Application of antiemetic drugs
Exhibit 02: Major antiemetic drug class
Exhibit 03: Global antiemetic drugs market snapshot 2016
Exhibit 04: Steps involved in emesis
Exhibit 05: Mechanism of emesis
Exhibit 06: Causes of emesis
Exhibit 07: Global antiemetic drug market snapshot
Exhibit 08: Global antiemetic drugs market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global antiemetic drugs market
Exhibit 10: Five forces analysis
Exhibit 11: Pipeline analysis of vendors in Phase I
Exhibit 12: Pipeline analysis of vendors in Phase II
Exhibit 13: Pipeline analysis of vendors in Phase III
Exhibit 14: Key clinical trials
Exhibit 15: Market segmentation by application 2016
Exhibit 16: Global antiemetic chemotherapeutic drugs market 2016-2021 ($ millions)
Exhibit 17: Global antiemetic surgery treatment market 2016-2021 ($ millions)
Exhibit 18: Global antiemetic gastroenteritis drugs market 2016-2021 ($ millions)
Exhibit 19: Various emetics symptoms
Exhibit 20: Global antiemetic other drugs market 2016-2021 ($ millions)
Exhibit 21: Segmentation of global antiemetic drugs market by drug class 2016
Exhibit 22: Other drug classes of antiemetic drugs market
Exhibit 23: Segmentation of global antiemetic drugs market by geography 2016 and 2021
Exhibit 24: Segmentation of global antiemetic drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 25: Market scenario in Americas
Exhibit 26: Antiemetic drugs market in Americas 2016-2021 ($ millions)
Exhibit 27: Market scenario in EMEA
Exhibit 28: Antiemetic drugs market in EMEA 2016-2021 ($ millions)
Exhibit 29: Market scenario in APAC
Exhibit 30: Antiemetic drugs market in APAC 2016-2021 ($ millions)
Exhibit 31: Factors causing PONV
Exhibit 32: Triggers and therapeutics for CINV
Exhibit 33: Revenue of Kytril marketed by F. Hoffmann-La Roche 2014-2016 ($ millions)
Exhibit 34: Competitive structure analysis of global antiemetic drug market 2016
Exhibit 35: Competitive factors of global antiemetic drugs market
Exhibit 36: Market penetration of various global antiemetic drugs manufacturers 2016
Exhibit 37: Strategic success factors of companies in global antiemetic drugs market
Exhibit 38: GSK: Key highlights
Exhibit 39: GlaxoSmithKline: Strength assessment
Exhibit 40: GlaxoSmithKline: Strategy assessment
Exhibit 41: GlaxoSmithKline: Opportunity assessment
Exhibit 42: Johnson & Johnson: Key highlights
Exhibit 43: Johnson & Johnson: Strength assessment
Exhibit 44: Johnson & Johnson: Strategy assessment
Exhibit 45: Johnson & Johnson: Opportunity assessment
Exhibit 46: Pfizer: Key highlights
Exhibit 47: Pfizer: Strength assessment
Exhibit 48: Pfizer: Strategy assessment
Exhibit 49: Pfizer: Opportunity assessment
Exhibit 50: Sanofi: Key highlights
Exhibit 51: Sanofi: Strength assessment
Exhibit 52: Sanofi: Strategy assessment
Exhibit 53: Sanofi opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • bbott
  • Eisai
  • Glenmark
  • IPCA Laboratories
  • Merck
  • RedHill
  • MORE
New Research Report - Global Antiemetic Drug Market 2017-2021

Other Prominent Vendors in the market are: bbott, Bristol-Myers Squibb, Cipla, Eisai, Eli Lilly, Glenmark, Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin, Merck, Novartis, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of antiemetic drug market. These inorganic growth strategies include global M&A, partnerships, and regional acquisition. Owing to these inorganic growth strategies, the market penetration of vendors is improved, technological advancement due to mutual collaboration in R&D, and improved the product portfolio.”

According to the report, one of the major drivers for this market is increased prevalence of cancer. With this ever-increasing population of cancer patients, effective therapies are necessary to save lives and improve their quality of life. Chemotherapy is widely used therapy to help individuals fight cancer. The data estimated that around 3.8-4.2 million cancer patients undergo chemotherapy treatment every year. However, chemotherapy is associated with many side effects. The majority of chemotherapeutic agents cause serious nausea and vomiting with its treatment. This is termed as CINV. The data also reported that around eight out 10 patients undergoing chemotherapy encounter CINV as a debilitating side effect. It is one of the major factors for premature discontinuation of chemotherapy.

Further, the report states that one of the major factors hindering the growth of this market is lack of animal models. Nausea and vomiting are most common symptoms associated either as a symptom of a disease or the side effect of a various class of drugs. The development of newer antiemetic drugs and analyzing emetic liability in novel chemical entities mainly rely on the models that mimic the complexity of these multi-system reflexes. Animal models in preclinical studies are widely used for examining the safety, efficacy, and toxicity of molecule under examination before evaluating it on human volunteers.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • bbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai
  • Eli Lilly
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • IPCA Laboratories
  • Lupin
  • Merck
  • Novartis
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll